SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Novo Reports 25% Mean Weight Loss Among Early CagriSema Responders

Novo Nordisk said a post hoc analysis of the REDEFINE 1 trial presented at ObesityWeek 2026 found CagriSema was associated with 25% mean weight loss among early responders.

NOVOB

Related stories